细胞株开发市场规模、份额、成长分析、按产品类型、按来源、按应用、按地区 - 产业预测，2024-2031 年

2022年，细胞株开发的全球市场规模为47亿美元，从2023年的51.6亿美元成长到2031年的109.4亿美元，预计在预测期内（2024-2031年）将以复合年增长率增长。 9.84%。

由于该领域的快速发展以及对创新细胞技术和产品的投资增加，细胞株开发市场预计将显着成长。全球对个人化医疗的需求不断增长，加上细胞研究投资的增加，正在为该领域的提供者创造新的机会。此外，对治疗各种疾病的生物相似药和生技药品的需求不断增长，预计将进一步增强细胞株开发公司的未来性。未来几年，专注于创造旨在改善医疗保健结果的新型药物、疗法和疫苗可能会刺激该领域的需求。此外，基因编辑技术的快速应用为专门从事细胞株开发的公司提供了良好的前景。然而，高开发成本、道德困境和可扩展性障碍等挑战对整个预测期内及以后的市场成长构成了潜在障碍。总体而言，由于技术进步的融合、对先进医疗解决方案的需求不断增加以及由于增长和机会而不断追求医疗保健创新，细胞株开发市场面临着多项挑战。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 价值链分析
• 市场生态系统
• 案例研究分析
• 监管环境
• 创新矩阵
• 主要投资分析
• 关键成功因素
• 竞争程度

细胞株开发市场：按类型

• 市场概况
• 初代细胞系
• 连续性细胞株
• 融合瘤
• 重组细胞株

细胞株开发市场：依产品分类

• 市场概况
• 按设备
  • 生物安全柜
  • 细胞计数器和活力分析系统
  • 培养箱
  • 离心机
  • 反应器
  • 仓储设备
  • 冰箱/冷冻库
  • 冷冻系统
  • 自动化系统
  • 显微镜
  • 过滤系统
  • 其他设备
• 按介质和试剂
  • 血清
  • 牛（FBS）
  • 牛血清（ABS）
  • 其他动物血清
  • 中等的
  • 最低所需介质 (MEM)
  • 减少血清培养基
  • 无血清培养基（SFM）
  • 试剂
  • 补充品和生长因子
  • 缓衝液和化学品
  • 细胞分离试剂
  • 冻存试剂
  • 其他试剂

细胞株开发市场：依来源分类

• 市场概况
• 哺乳动物的
• 昆虫
• 两栖类

细胞株开发市场：依应用分类

• 市场概况
• 生物生产
  • 诊断
  • 疫苗生产
  • 重组蛋白疗法
• 组织工程与再生医学
• 毒性试验
• 研究
• 药物发现
  • 目标检验
  • 疾病模型
  • 药物筛检与开发

细胞株开发市场：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• American Type Culture Collection（ATCC）（US）
• Corning, Inc.（US）
• European Collection of Cell Cultures（ECACC）（UK）
• GE Healthcare（US）
• Lonza Group AG（Switzerland）
• Sartorius AG（Germany）
• JSR Life Sciences（US）
• MERCK KGaA（Germany）
• Thermo Fisher Scientific, Inc.（US）
• Wuxi Apptec（China）
• Celltrion, Inc.（South Korea）
• Bio-Techne Corporation（US）
• Charles River Laboratories International, Inc.（US）
• Eppendorf AG（Germany）
• Fujifilm Diosynth Biotechnologies（Japan）
• Promega Corporation（US）
• Danaher Corporation（US）
• Thermo Fisher Scientific（US）
• Perkin-Elmer（US）
• Cell Culture Technologies（US）
• Takara Bio Inc.（Japan）

Global Cell Line Development Market size was valued at USD 4.7 billion in 2022 and is poised to grow from USD 5.16 billion in 2023 to USD 10.94 billion by 2031, growing at a CAGR of 9.84% during the forecast period (2024-2031).

The cell line development market is poised for significant growth, driven by increasing investments in innovative cell technologies and products, alongside rapid advancements in the field. A rising global demand for personalized medicine, coupled with heightened investment in cell research, is paving the way for new opportunities for providers in this sector. Furthermore, the growing need for biosimilars and biologics to address an array of diseases is expected to further enhance prospects for cell line development firms. The focus on creating novel pharmaceuticals, therapeutics, and vaccines aimed at improving healthcare outcomes is likely to stimulate demand in this area in the coming years. Additionally, the burgeoning application of gene editing technologies presents lucrative prospects for companies specializing in cell line development. However, challenges such as high development costs, ethical dilemmas, and scalability hurdles pose potential barriers to market growth throughout the forecast period and beyond. Overall, while the cell line development market faces some challenges, the convergence of technological advancements, increasing demand for advanced medical solutions, and the ongoing pursuit of innovation in healthcare are set to create a robust environment for growth and opportunity.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Line Development market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell Line Development Market Segmental Analysis

Global Cell Line Development Market is segmented by Type, Product, Source, Application, and region. Based on Type, the market is segmented into Primary Cell Lines, Continuous Cell Lines, Hybridomas, and Recombinant Cell Lines. Based on Product, the market is segmented into Equipment, and Media & Reagents. Based on Source, the market is segmented into Mammalian, Insect, Amphibian. Based on Application, the market is segmented into Bioproduction, Tissue Engineering & Regenerative Medicine, Toxicity Testing, Research, Drug Discovery. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Cell Line Development Market

The global cell line development market is driven by the escalating investments in cell research, as healthcare researchers strive to harness the intricacies of cellular functions for innovative therapeutic solutions. This emphasis on cell line development is paramount, as it underpins critical advancements in drug discovery, regenerative medicine, and personalized therapies. As researchers unlock the full potential of various cell types, the demand for specialized cell lines surges, further propelling the market. Additionally, the expanding biopharmaceutical industry seeks to capitalize on cell lines for vaccine production and bioproduction, reinforcing the significant growth prospects within this dynamic market landscape.

Restraints in the Global Cell Line Development Market

The Global Cell Line Development market faces significant restraints primarily due to the complexity and intricacy involved in developing cell lines, resulting in high operational costs. The need for advanced technologies not only escalates financial investments but also requires specialized personnel and equipment, creating barriers for entry and competition. Additionally, ensuring consistency in cell line quality presents further challenges, leading to potential delays in research and production timelines. These factors collectively contribute to heightened development expenses and may deter companies from pursuing cell line development projects, thereby impacting overall market growth and demand in this sector.

Market Trends of the Global Cell Line Development Market

The Global Cell Line Development market is experiencing a notable trend towards 3D cell culture and organoid development, driven by the increasing demand for more accurate and physiologically relevant models in drug discovery and disease research. This shift is prompting cell line development companies to innovate and refine their offerings, focusing on specialized services and products that cater to the growing need for advanced 3D culture systems. By aligning their strategies with the proliferation of organoid technologies, these companies are poised to capture substantial market opportunities and enhance their competitive edge, underscoring a significant pivot towards advanced biotechnological solutions in cell line development.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Cell Line Development Market by Type

• Market Overview
• Primary Cell Lines
• Continuous Cell Lines
• Hybridomas
• Recombinant Cell Lines

Cell Line Development Market by Product

• Market Overview
• By Equipment
  • Biosafety Cabinets
  • Cell Counters & Viability Analysis Systems
  • Incubators
  • Centrifuges
  • Bioreactors
  • Storage Equipment
  • Refrigerators & Freezers
  • Cryostorage Systems
  • Automation Systems
  • Microscopes
  • Filtration Systems
  • Other Equipment
• By Media & Reagents
  • Sera
  • Fetal Bovine Sera (FBS)
  • Adult Bovine Sera (ABS)
  • Other Animal Sera
  • Media
  • Minimum Essential Media (MEM)
  • Reduced Serum Media
  • Serum-Free Media (SFM)
  • Reagents
  • Supplements & Growth Factors
  • Buffers & Chemicals
  • Cell Dissociation Reagents
  • Cryopreservative Reagents
  • Other Reagents

Cell Line Development Market by Source

• Market Overview
• Mammalian
• Insect
• Amphibian

Cell Line Development Market by Application

• Market Overview
• Bioproduction
  • Diagnostics
  • Vaccine Production
  • Recombinant Protein Therapeutics
• Tissue Engineering & Regenerative Medicine
• Toxicity Testing
• Research
• Drug Discovery
  • Target Validation
  • Disease Modeling
  • Drug Screening and Development

Cell Line Development Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• American Type Culture Collection (ATCC) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corning, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• European Collection of Cell Cultures (ECACC) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JSR Life Sciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MERCK KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuxi Apptec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eppendorf AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth Biotechnologies (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Perkin-Elmer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cell Culture Technologies (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments